JP2020511521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511521A5 JP2020511521A5 JP2019552611A JP2019552611A JP2020511521A5 JP 2020511521 A5 JP2020511521 A5 JP 2020511521A5 JP 2019552611 A JP2019552611 A JP 2019552611A JP 2019552611 A JP2019552611 A JP 2019552611A JP 2020511521 A5 JP2020511521 A5 JP 2020511521A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- therapeutic
- concentration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024093487A JP2024116286A (ja) | 2017-03-23 | 2024-06-10 | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475477P | 2017-03-23 | 2017-03-23 | |
| US62/475,477 | 2017-03-23 | ||
| PCT/US2018/024096 WO2018175932A1 (en) | 2017-03-23 | 2018-03-23 | Systems and methods for nucleic acid expression in vivo |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024093487A Division JP2024116286A (ja) | 2017-03-23 | 2024-06-10 | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511521A JP2020511521A (ja) | 2020-04-16 |
| JP2020511521A5 true JP2020511521A5 (https=) | 2021-05-06 |
Family
ID=63585790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552611A Pending JP2020511521A (ja) | 2017-03-23 | 2018-03-23 | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
| JP2024093487A Pending JP2024116286A (ja) | 2017-03-23 | 2024-06-10 | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024093487A Pending JP2024116286A (ja) | 2017-03-23 | 2024-06-10 | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11541130B2 (https=) |
| EP (1) | EP3600428A4 (https=) |
| JP (2) | JP2020511521A (https=) |
| CN (2) | CN110678202B (https=) |
| CA (1) | CA3057320A1 (https=) |
| WO (1) | WO2018175932A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| JP7014721B2 (ja) | 2015-09-18 | 2022-02-01 | ディーエヌエーアールエックス | インビボでの核酸発現のためのシステム及び方法 |
| EA201891317A3 (ru) | 2015-11-30 | 2019-04-30 | Дьюк Юниверсити | Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2018017754A1 (en) | 2016-07-19 | 2018-01-25 | Duke University | Therapeutic applications of cpf1-based genome editing |
| EP3600428A4 (en) * | 2017-03-23 | 2020-08-26 | Dnarx | SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102625470B1 (ko) * | 2017-05-31 | 2024-01-16 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 ix 유전자 발현 카세트 및 이의 사용 |
| WO2019144061A1 (en) | 2018-01-19 | 2019-07-25 | Duke University | Genome engineering with crispr-cas systems in eukaryotes |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020206162A1 (en) * | 2019-04-03 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| WO2021253180A1 (en) | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| CN111863118B (zh) * | 2020-07-20 | 2023-09-05 | 湖南莱博赛医用机器人有限公司 | 基于tct制片进行tct和dna倍体分析的方法 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| CN116615233A (zh) * | 2020-09-25 | 2023-08-18 | Dnarx公司 | 用于使生物分子在受试者中表达的系统和方法 |
| JP2023548746A (ja) * | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| US20230212610A1 (en) * | 2021-12-20 | 2023-07-06 | DNARx | Nucleic acid expression using subcutaneous administration |
| CN115992211B (zh) * | 2022-08-10 | 2025-07-29 | 南京鼓楼医院 | 一种用于狼疮性肾炎诊断的血清外泌体tsRNA标志物、探针及其应用 |
| WO2024102972A1 (en) * | 2022-11-11 | 2024-05-16 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| CN115851911B (zh) * | 2022-11-25 | 2025-10-24 | 南京鼓楼医院 | 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6806084B1 (en) * | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| US6133026A (en) | 1996-05-31 | 2000-10-17 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
| US6413544B1 (en) | 1996-08-19 | 2002-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US6074667A (en) * | 1996-11-20 | 2000-06-13 | Kinnunen; Paavo | Liposomal transfection method |
| US20020065213A1 (en) * | 1998-01-16 | 2002-05-30 | Robert J. Debs | Methods and compositions for nonviral gene delivery |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| AU5911899A (en) | 1998-09-09 | 2000-03-27 | Genzyme Corporation | Methylation of plasmid vectors |
| US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| EP1250156A4 (en) * | 2000-01-19 | 2004-03-31 | Genteric Inc | METHOD FOR TRANSFECTING NUCLEIC ACID IN CELLS |
| WO2001085996A1 (en) | 2000-05-09 | 2001-11-15 | Isis Pharmaceuticals, Inc. | Methods of obtaining active antisense compounds |
| US7083782B2 (en) | 2000-07-19 | 2006-08-01 | Pepgen Corporation | Method of treatment using interferon-tau |
| AU2001290984A1 (en) | 2000-09-18 | 2002-04-02 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| FR2821855B1 (fr) | 2001-03-09 | 2004-04-02 | Cayla | Genes synthetiques et plasmides bacteriens depourvus de cpg |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| EP2397563A3 (en) | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| US20070087045A1 (en) * | 2005-10-14 | 2007-04-19 | Industrial Technology Research Institute | Lipid carrier and method of preparing the same |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| EP2061514B1 (en) * | 2006-08-29 | 2014-11-26 | Council of Scientific & Industrial Research | An aqueous formulation for possible selective targeting and delivering gene to cancer cells |
| WO2009061515A1 (en) | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| EP2454368A4 (en) | 2009-07-17 | 2013-01-09 | Aaron Thomas Tabor | COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE |
| CN101812177B (zh) * | 2010-01-05 | 2012-01-25 | 中国药科大学 | 类固醇激素修饰的阳离子聚合物及其基因复合物的制备 |
| CN102366411B (zh) * | 2011-09-14 | 2012-12-19 | 海南灵康制药有限公司 | 一种地塞米松棕榈酸酯脂质体注射液 |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| US20160194660A1 (en) | 2012-12-21 | 2016-07-07 | Merck Sharp & Dohme Corp. | Expression vectors for recombinant protein production in mammalian cells |
| KR20250012194A (ko) * | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| EP3686279B1 (en) * | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
| WO2016089862A1 (en) * | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| JP7014721B2 (ja) | 2015-09-18 | 2022-02-01 | ディーエヌエーアールエックス | インビボでの核酸発現のためのシステム及び方法 |
| EP3600428A4 (en) | 2017-03-23 | 2020-08-26 | Dnarx | SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO |
| CN116615233A (zh) | 2020-09-25 | 2023-08-18 | Dnarx公司 | 用于使生物分子在受试者中表达的系统和方法 |
-
2018
- 2018-03-23 EP EP18770192.5A patent/EP3600428A4/en active Pending
- 2018-03-23 WO PCT/US2018/024096 patent/WO2018175932A1/en not_active Ceased
- 2018-03-23 CA CA3057320A patent/CA3057320A1/en active Pending
- 2018-03-23 CN CN201880027828.2A patent/CN110678202B/zh active Active
- 2018-03-23 US US15/934,587 patent/US11541130B2/en active Active
- 2018-03-23 CN CN202310347530.2A patent/CN116392609A/zh active Pending
- 2018-03-23 JP JP2019552611A patent/JP2020511521A/ja active Pending
-
2022
- 2022-10-27 US US18/050,389 patent/US20240033376A1/en active Pending
-
2024
- 2024-06-10 JP JP2024093487A patent/JP2024116286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511521A5 (https=) | ||
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| Khan et al. | Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature | |
| Vicentini et al. | Delivery systems and local administration routes for therapeutic siRNA | |
| JP5863670B2 (ja) | 核酸および／または他の構成要素を含有している合成ナノ構造体 | |
| JP6023126B2 (ja) | 標的遺伝子の発現を抑制する組成物 | |
| Wang et al. | Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations | |
| Xue et al. | Engineered macrophage membrane‐enveloped nanomedicine for ameliorating myocardial infarction in a mouse model | |
| US20170232115A1 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof | |
| JP6538031B2 (ja) | 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療 | |
| JP2018510621A5 (https=) | ||
| JP2013224311A (ja) | がん細胞および癌随伴線維芽細胞への標的化剤 | |
| Rodriguez-Gascon et al. | Vaginal gene therapy | |
| CN109125306B (zh) | 靶向肝癌的自噬siRNA-Fingolimod共递送脂质纳米颗粒 | |
| WO2018193902A1 (ja) | マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果 | |
| AU2018314236A1 (en) | RNA aptamers against transferrin receptor (TfR) | |
| Han et al. | Enhancing Cardioprotection Through Neutrophil‐Mediated Delivery of 18β‐Glycyrrhetinic Acid in Myocardial Ischemia/Reperfusion Injury | |
| Okuda et al. | Targeted therapy for acute autoimmune myocarditis with nano-sized liposomal FK506 in rats | |
| Chatterjee et al. | siRNA-based novel therapeutic strategies to improve effectiveness of antivirals: an insight | |
| Nomani et al. | RNA-lipid nanoparticle therapeutics for women’s health | |
| JP2017521374A5 (https=) | ||
| Subasic et al. | Dose-dependent production of anti-PEG IgM after intramuscular PEGylated-hydrogenated soy phosphatidylcholine liposomes, but not lipid nanoparticle formulations of DNA, correlates with the plasma clearance of PEGylated liposomal doxorubicin in rats | |
| US12472151B2 (en) | Delivery compositions, and methods of making and using same | |
| JP7577335B2 (ja) | 肺炎症治療用のナノキャリア | |
| Peng et al. | Engineered small extracellular vesicles for targeted delivery of perlecan to stabilise the blood–spinal cord barrier after spinal cord injury |